ImmunicIMUX
IMUX
About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Employees: 90
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
993% more call options, than puts
Call options by funds: $1.25M | Put options by funds: $114K
3% less funds holding
Funds holding: 66 [Q4 2024] → 64 (-2) [Q1 2025]
11.8% less ownership
Funds ownership: 56.7% [Q4 2024] → 44.91% (-11.8%) [Q1 2025]
14% less capital invested
Capital invested by funds: $51.1M [Q4 2024] → $44.1M (-$6.99M) [Q1 2025]
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
521%
upside
Avg. target
$8.33
935%
upside
High target
$10
1,142%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 1,142%upside $10 | Buy Maintained | 5 Jun 2025 |
B. Riley Securities William Woods | 521%upside $5 | Buy Reiterated | 23 May 2025 |
HC Wainwright & Co. Matthew Caufield | 1,142%upside $10 | Buy Reiterated | 1 May 2025 |
Financial journalist opinion
Based on 10 articles about IMUX published over the past 30 days
Positive
Seeking Alpha
5 days ago
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results.
Positive
Proactive Investors
1 week ago
Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for its Phase 3 ENSURE program targeting relapsing multiple sclerosis (MS). The ENSURE-1 and ENSURE-2 trials, described as "twin studies," have collectively enrolled over 2,000 patients across 15 countries.
Positive
Proactive Investors
1 week ago
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials
Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE program includes two identical, multicenter, randomized, double-blind phase 3 trials, ENSURE-1 and ENSURE-2, designed to assess the efficacy, safety, and tolerability of vidofludimus calcium compared to placebo in patients with RMS.
Neutral
PRNewsWire
1 week ago
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential – – New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes – NEW YORK , June 5, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results. Enrollment Completed for Both Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis (RMS) The ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients.
Positive
Proactive Investors
1 week ago
Immunic raises $65M in public offering to fund clinical trials
Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offering, raising approximately $65 million in initial proceeds. The offering consisted of pre-funded warrants, Series A warrants, and Series B warrants to purchase shares of common stock or additional pre-funded warrants.
Neutral
PRNewsWire
1 week ago
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
NEW YORK , June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The Pre-Funded Warrants are immediately exercisable, and may be exercised at any time after their original issuance.
Neutral
PRNewsWire
1 week ago
Immunic to Participate in Investor, Scientific and Industry Conferences in June
NEW YORK , June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June: June 3-5: Jefferies Healthcare Conference. Daniel Vitt, Ph.D.
Neutral
Proactive Investors
2 weeks ago
Immunic unveils pricing of $65M underwritten public offering
Immunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65 million in gross proceeds, which the company plans to use to support its clinical trials, operations, and other general corporate purposes. The offering consists of pre-funded warrants, Series A warrants, and Series B warrants sold together at a combined public offering price of $0.7499.
Neutral
PRNewsWire
2 weeks ago
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
NEW YORK , May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The combined public offering price of one Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant, which are being sold together but are immediately seperable, is $0.7499.
Neutral
PRNewsWire
2 weeks ago
Immunic, Inc. Announces Proposed Public Offering
NEW YORK , May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares of common stock (or pre-funded warrants) expiring on December 31, 2025, (iii) and Series B warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. The Series A and B warrants will immediately expire in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to September 30, 2025, subject to certain exceptions.
Charts implemented using Lightweight Charts™